The Notch ligand delta-like ligand 4 (DLL4) is an essential component expressed by endothelial tip cells during angiogenic sprouting. We have described a conceptually novel therapeutic strategy for targeting tumor angiogenesis and endothelial tip cells based on DNA vaccination against DLL4. Immunization with DLL4-encoding plasmid DNA by in vivo electroporation severely retarded the growth of orthotopically implanted mammary carcinomas in mice by induction of a nonproductive angiogenic response. Mechanistically, vaccination brought about a break in tolerance against the self-antigen, DLL4, as evidenced by the production of inhibitory and inherently therapeutic antibodies against mouse DLL4. Importantly, no evidence for a delayed wound healing response, or for toxicity associated with pharmacological blockade of DLL4 signaling, was noted in mice immunized with the DLL4 vaccine. We have thus developed a well-tolerated DNA vaccination strategy targeting the endothelial tip cells and the antigen DLL4 with proven therapeutic efficacy in mouse models of mammary carcinoma; a disease that has been reported to dramatically induce the expression of DLL4. Conceivably, induction of immunity toward principal mediators of pathological angiogenesis could provide protection against recurrent malignant disease in the adjuvant setting.
Introduction
The most widely used target for developing antiangiogenic regimens of therapeutic value in cancer is vascular endothelial growth factor (VEGF), because of its well-documented role in promoting endothelial cell growth, migration and sprouting (Pourgholami and Morris, 2008) . Recently, signaling by delta-like ligand 4 (DLL4) through its receptor Notch1 was identified as an equally critical component of physiological and pathological neovascularization (Noguera-Troise et al., 2006; Ridgway et al., 2006; Hellstrom et al., 2007; Scehnet et al., 2007) . DLL4 is specifically induced by VEGF in sprouting endothelial cells, wherein it orchestrates the formation of proper angiogenic sprouts. Blockade of DLL4 function results in hypersprouting due to the loss of lateral inhibition of the endothelial tip cell phenotype mediated through Notch1. As a consequence, an excessive, but nonproductive, angiogenic response is mounted, characterized by poor perfusion that results in hypoxia. In experimental tumors, DLL4 signaling to Notch1 in the endothelium acts to improve vascular function (Li et al., 2007) . Conversely, neutralization of DLL4 activity impairs tumor growth in preclinical models, both as a single agent and in combination with VEGF inhibition (Noguera-Troise et al., 2006; Ridgway et al., 2006) . Little is known about the localization of DLL4 in human tissues. However, DLL4 is selectively expressed by the endothelium of malignant tissues, but not the normal counterparts in breast and colon (Jubb et al., 2009 (Jubb et al., , 2010 .
Over recent years the idea of exploiting the immune system to fight cancer has been extensively developed. Therapeutic cancer vaccination has been performed using a wide variety of vaccine modalities from peptides or recombinant proteins representing tumor-associated antigens, to vaccines consisting of autologous tumor cells (Pejawar-Gaddy and Finn, 2008) . In humans, vaccination studies using both recombinant protein (Ullenhag et al., 2004) and genetic viral vector vaccines (Schlom et al., 2007) have resulted in prolonged patient survival. Genetic vaccination, that is, the transfer of a genetically encoded antigen for uptake and translation in the host cell, is a novel and promising method of immunization against both malignant and infectious diseases (Liu et al., 2006) . In addition to advantages, such as the possibility of concurrent use of multiple antigens and ease of modification and production, the inherent properties of the prokaryotic DNA backbone also results in stimulation of the innate immune system, thereby providing additional adjuvant properties during the immunization (Liu et al., 2006) . Several veterinarian DNA vaccines have been approved for routine use, including a West Nile virus vaccine for horses (Davis et al., 2001 ) and a vaccine for the treatment of advanced canine melanoma (Bergman et al., 2003) . These, together with a recent study showing that plasmid DNA vaccination in humans results in protection against influenza challenge (Jones et al., 2009) , clearly show the therapeutic potential of plasmid DNA vaccination.
In this study, we have described the development of a DNA vaccination strategy targeting the tumor endothelial tip cells through immunization with plasmid DNA encoding DLL4. Immunization of mice by in vivo electroporation attenuated tumor growth in two orthotopic mouse models of ERBB2-expressing mammary carcinoma. In seeking the mechanism for the observed effects, we found that vaccination against DLL4 resulted in a disproportionate and poorly perfused vascular bed due to the induction of a potent and inhibitory humoral response against the self-antigen, DLL4. Importantly, mice immunized with DLL4 cDNA did not exhibit a delay in wound healing, indicating that physiological angiogenesis was not affected by the vaccination strategy. Thus, our study identifies DNA vaccination against tumor angiogenesis by targeting of DLL4 as a promising and well-tolerated approach for further development toward clinical trials.
Results
Xenogeneic DNA immunization by intradermal electroporation induces a humoral immune response to DLL4 To generate the DLL4 plasmid vaccine, we cloned the cDNA encoding human DLL4 into the pVAX1 expression vector (DLL4 vaccine), which is specifically designed for the development of DNA vaccines and approved for use in humans. Expression of DLL4 protein was confirmed by western blot analysis of the lysates from HeLa cells transfected with the DLL4 plasmid ( Figure 1a) . Next, we immunized mice using one out of two different protocols (Figure 1b) . One cohort of mice were immunized three times 4 weeks apart by injecting 40 mg of DLL4 vaccine or empty vector intradermally in the flank at two locations, followed by in vivo electroporation at each injection site (hereafter designated immunization protocol 1). A second cohort of mice received two injections of 80 mg of DLL4 vaccine by intramuscular injection 4 weeks apart, and a final immunization by injection of 40 mg of DLL4 vaccine intradermally at two locations, followed by in vivo electroporation at each injection site (hereafter designated immunization protocol 2). No overt adverse effects of the immunization protocols on the well-being of the mice were noted. To verify whether the immunization strategies were successful, we analyzed sera from immunized mice for antibodies against human DLL4 by enzyme-linked immunosorbent assay . In contrast to sera from mice immunized with empty vector, sera from mice immunized by either protocol 1 or protocol 2 contained antibodies recognizing the recombinant extracellular domain of human DLL4 at readily detectable titers (Figure1c; data not shown).
Vaccination against the endothelial tip cell antigen DLL4 is therapeutically efficacious in mammary carcinoma To investigate whether immunization of mice with the DLL4 plasmid holds therapeutic value, we made use of orthotopic models of ERBB2-expressing mouse mam- Targeting endothelial tip cells by DNA vaccination BK Haller et al mary carcinoma. D2F2/E2 cells were derived from a spontaneous mammary tumor in a BALB/c mouse and were transfected with the cDNA encoding ERBB2 (Wei et al., 1999) . Immunostaining analysis showed that DLL4 was highly and specifically expressed in the vasculature of D2F2/E2 tumors (Figure 2a ). Mice immunized with empty vector or DLL4 vaccine were challenged orthotopically with tumors 1 week after the last immunization by injection of D2F2/E2 cells into the fourth inguinal mammary fat pad. Immunization by protocol 1 resulted in a significant delay in tumor growth compared with the growth of tumors in mice immunized with empty vector (Figure 2b ; Po0.01). At the conclusion of the experiment, control mice presented with an average tumor volume of 372 ± 141 mm 3 , whereas mice injected with the DLL4 vaccine exhibited an average tumor volume of 134±84 mm 3 . Similarly, tumor growth in mice immunized by protocol 2 was significantly delayed, and at the end of the trial the average tumor volume was 143±112 mm 3 (Figure 2b ; Po0.05). In a separate study, tumor growth in mice vaccinated against DLL4 was recorded for a prolonged period of time following euthanasia of the vectorimmunized mice because of ethical considerations. Tumors in vaccinated mice continued to grow, albeit at a reduced pace, and at the end of the study the growth delay compared with the control group was 11 days (Figure 2c) . Importantly, impaired tumor growth following DNA vaccination against DLL4, using either protocol, was also observed in mice injected orthotopically with the ERBB2-expressing mouse mammary carcinoma cell line, TUBO (Figure 2d ; Po0.05).
Taken together, we have shown the therapeutic efficacy of DNA vaccination against DLL4 in two different mouse models of ERBB2-expressing mammary carcinoma.
Immunization with DLL4 vaccine promotes nonproductive angiogenesis Following completion of the therapeutic trials, tumors were excised, inspected for gross phenotypical changes and prepared for histological analysis. Overt thrombotic events on the surface of the tumor were detected for a majority of tumors from mice immunized with DLL4 vaccine, whereas none of the vector-immunized mice presented with tumors showing thrombosis ( Figure 3a) . Next, we performed immunostaining for the endothelial cell antigen, CD31, to examine the vascularity of the tumors. In line with the previous studies using DLL4-blocking agents (Noguera-Troise et al., 2006; Ridgway et al., 2006) , D2F2/E2 tumors from mice immunized with DLL4 cDNA either by protocol 1 or by protocol 2 exhibited a 60 and 75% higher vascular density, respectively, compared with tumors from mice immunized with empty vector (Figure 3b ; data not shown; Po0.01). Similar results were obtained in TUBO tumors (data not shown). To investigate the functionality of the tumor vasculature, we perfused tumor-bearing mice systemically with fluorescein-labeled tomato lectin. The vascular bed in tumors from mice immunized with the DLL4 vaccine was largely nonfunctional, as witnessed by a fraction perfused vascular area of 11 ± 1% (Figure 3c ). In contrast, tumors from mice immunized with empty vector exhibited a fraction perfused vascular area of 41 ± 13% (Figure 3c ; Po0.01). Notably, large blood vessels were preferentially perfused in mice inoculated with the DLL4 vaccine ( Figure 3c ). Finally, we assessed the apoptotic index of D2F2/E2 tumors from vector-or DLL4-immunized mice by immunostaining for activated caspase-3. There was a significant 2.2-fold increase in the apoptotic rate of tumor cells following vaccination against DLL4 (Figure 3d ; Po0.05). Importantly, co-staining with the vascular marker, CD31, indicated that there was no change in the Thus, we determined that DNA vaccination against DLL4 leads to promotion of nonproductive angiogenesis in tumors, giving rise to an increased apoptotic rate of tumor cells.
Inhibition of tumor growth is mediated by a humoral response against DLL4
In order to elucidate the mechanism whereby immunization with the DLL4 plasmid DNA elicits a therapeutic effect, we performed a series of studies aimed at investigating the specific role for a T cell-and/or a B cell-mediated immune response. Mice were immunized with empty vector or the DLL4 vaccine, after which the spleen was excised and a single cell splenocyte suspension was prepared. Mouse DLL4-specific T cell activity was assessed by IFN-g ELISpot after stimulation of the splenocytes with recombinant extracellular portion of mouse DLL4 or with a pool of mouse DLL4-derived peptides predicted to bind with a high affinity to the H2-K d and H2-D d MHC class I molecules expressed by BALB/c mice. In contrast to the splenocytes polyclonally stimulated with concanavalin A, which produced high levels of IFN-g, there was no discernible induction of IFN-g in splenocytes by the DLL4-derived peptides, regardless of previous immunization with the DLL4 cDNA (Figure 4a ). However, splenocytes from mice that received the DLL4 vaccine showed a higher basal level of IFN-g after tumor challenge, compared with mice vaccinated with empty vector (Figure 4b ; Po0.001 for protocol 1, Po0.01 for protocol 2). To assess whether a T cell-mediated response toward DLL4 was part of the effector mechanism for the therapeutic efficacy, we depleted CD4 þ or CD8 þ T cells before the tumor challenge by injection of antibodies for CD4 or CD8 in immunized mice. Following two injections of antibodies, CD4 þ and CD8 þ T cells were depleted by 99.5 and 99.6%, respectively, as assessed by flow cytometry (Figure 4c) . Notably, upon depletion of T cells, the therapeutic efficacy of the DLL4 vaccine on the growth of orthotopically implanted D2F2/E2 mammary carcinomas was not diminished, indicating that T cells do not have a primary part in the beneficial effects (Figure 4d ; Po0.01 for all DLL4-immunized groups vs control). This finding was consistent with a lack of increased infiltration of immune cells into D2F2/E2 or TUBO tumors of vaccinated mice, as assessed by immunostaining for CD45 (data not shown).
Next, we analyzed the serum from mice immunized with empty vector or the DLL4 plasmid for the presence of antibodies reactive against mouse DLL4 using enzyme-linked immunosorbent assay. The serum of control-immunized mice did not contain immunoglobulins against DLL4 (Figure 5a) . In sharp contrast, all analyzed sera from mice that had received the DLL4 vaccine, by either protocol, exhibited high titers of antibodies specific for mouse DLL4 (Figure 5a ). We further assessed the potential of the antibodies present in the serum from DLL4-immunized mice to interfere with DLL4 signaling during developmental retinal angiogenesis. Injection of DLL4 immune serum into P3 pups instigated a thicker retinal capillary network with an increased number of branch points and tip cells compared with vector immune serum at P5 (Figure 5b) , indicative of the presence of neutralizing antibodies toward mouse DLL4. Finally, to investigate whether the DLL4 immune serum was inherently therapeutic, we treated naı¨ve D2F2/E2 tumor-bearing mice. Strikingly, the serum from DLL4-immunized mice significantly retarded tumor growth, compared with the serum from control-immunized mice (Figure 5c ; Po0.01), suggesting that the therapeutic efficacy of the vaccine is mediated through a humoral response against mouse DLL4.
In summary, we have developed an immunization strategy that can break tolerance to the endothelial tip cell antigen, DLL4, thereby resulting in the induction of DLL4-specific inhibitory antibodies that harbor therapeutic activity.
Vaccination against DLL4 is not associated with toxicity or delayed wound healing A recent study of pharmacological blockade of DLL4 signaling using antibodies, traps or g-secretase inhibitors reported toxicities, including liver cell atrophy, necrotic heart lesions and benign, subcutaneous ulcerating neoplasms, associated with long-term use (Yan et al., 2010) . To investigate whether vaccination against DLL4 gives rise to similar pathology, we performed necropsies on mice 5 months following their first immunization. Mice immunized with the DLL4 vaccine presented with livers indistinguishable from vector-immunized mice (Figure 6a ). In addition, no necrotic areas were noted in the hearts of mice vaccinated against DLL4 (data not shown). Moreover, in our studies using 480 mice immunized with the DLL4 vector, no ulcerating subcutaneous lesions were observed. Notably, no delay in the regrowth of the fur at the site of immunization was evident, and the puncture wounds from the electroporation procedure healed without complication.
One important factor to be considered for the development of vaccine-based approaches targeting the angiogenic vasculature is whether the inhibitory effect is limited to tumor angiogenesis, or extends also to physiological vessel formation. To address this question, we documented the healing process of full-thickness punch wounds in mice immunized with empty vector or the DLL4 vaccine. As depicted in Figure 6b , wound healing proceeded at a similar rate regardless of previous immunization, with wounds inflicted to DLL4-immunized mice reaching near complete closure marginally earlier compared with vector-immunized mice (Figure 6b ; Po0.05).
Taken together, no adverse events resulting from blockade of physiological DLL4 signaling in liver homeostasis or wound healing were evident in mice subjected to our vaccination strategy. 
were assessed by IFN-g ELISpot by stimulation of splenocytes with mouse DLL4 peptides or recombinant mouse extracellular portion of DLL4 (n ¼ 5 for each group). Recombinant carcinoembryonic antigen protein and carcinoembryonic antigen peptides were used as negative controls. The polyclonal stimulant concanavalin A (conA) was used as a positive control. The experiment was repeated three times. (b) Splenocyte activity in mice following immunization by protocol 1 (3 Â ID þ EP) or protocol 2 (2 Â IM, 1 Â ID þ EP) at the time of sacrifice after tumor challenge was assessed by IFN-g ELISpot without antigen-specific stimulation (vector, n ¼ 9; protocol 1, n ¼ 8; protocol 2, n ¼ 5). (c) Depletion of CD4 þ or CD8 þ cells was initiated three days before tumor challenge by injection of anti-CD4 or anti-CD8 antibodies and verified by flow cytometric analysis of peripheral blood 5 days after injection of antibodies. Tumor growth curve from vector-immunized mice was duplicated from Figure 2c , which depicts an experiment performed simultaneously to the T cell depletion experiment. (d) Growth of orthotopically implanted D2F2/E2 tumors in control mice and in mice depleted of CD4 þ /CD8 þ cells following vaccination with DLL4 plasmid DNA (n ¼ 6 for all groups). **Po0.01, ***Po0.001; Student's t-test.
Targeting endothelial tip cells by DNA vaccination BK Haller et al endothelial cell is necessary for the formation of an appropriate number of endothelial tip cells in relation to endothelial stalk cells (Hellstrom et al., 2007) . Hence, diminished Notch1 activation leads to superfluous formation of endothelial tip cells, and as a result, excessive angiogenic sprouting and a nonfunctional vasculature. Conversely, ectopic activation of Notch1 by DLL4 leads to tumor growth inhibition accompanied by hypovascularity (Segarra et al., 2008) . Our analyses showed that the vascular phenotype of tumors grown in mice inoculated with the DNA vaccine against DLL4 was similar to that of tumors from mice treated with DLL4-blocking antibodies, that is, increased vascular density paralleled by reduced vascular perfusion. In line with the enhanced, but nonproductive, angiogenic sprouting in tumors from immunized mice, perfusion was limited to the large blood vessels. Moreover, we found high titers of antibodies against mouse DLL4 in the serum following immunization with plasmid DNA encoding human DLL4; serum that was found to reproduce hallmark changes of inhibition of DLL4 signaling during developmental retinal angiogenesis, and to be inhibitory to tumor growth in naı¨ve mice. Notably, the potent humoral response against mouse DLL4 clearly shows that the xenogeneic vaccination strategy was able to break tolerance against the selfantigen, DLL4. However, despite our inability to show the presence of DLL4-specific T cells in vaccinated mice, splenocytes from immunized mice exhibited a higher basal production of IFN-g; the relevance of which remains undetermined. It is unclear which cell type is the source for IFN-g, but depletion of CD4 þ and CD8 þ T cells indicated that these cell types are of no consequence to the effector mechanism of the DLL4 vaccine in the models used. Whether other immune cells, such as natural killer cells, contribute to the IFN-g production and the antitumor effects remains to be investigated. The possibility to immunize against tumor angiogenesis is intriguing as vaccination would allow a semiprophylactic treatment approach, that is, prevention of recurrence in tumor-free patients, rather than treating already existing tumors. Long-term and potent immunity against crucial mediators of angiogenesis, such as DLL4, would conceivably result in the induction of a dormant, non-angiogenic state of disseminated micrometastases, and thereby a durable protection against recurrent growth without the need for chronic and costly pharmacological treatments with potential side effects. Indeed, the possibility of generating a long-term memory against tumor cell antigens following postsurgical vaccination was shown in colorectal cancer patients immunized with the carcinoembryonic antigen, in which the titer of antibodies 24 months after the last vaccination correlated with longer survival (Ullenhag et al., 2004) . Vaccination with the intent of preventing tumor angiogenesis has been performed by targeting various endothelial cell antigens, including VEGFR2, angiomotin and platelet-derived growth factor receptorb (Niethammer et al., 2002; Holmgren et al., 2006; Kaplan et al., 2006) . In this context, DLL4 represents a particularly attractive therapeutic target given the recent recognition of the vital role for endothelial tip cells in organizing the formation of the angiogenic sprout (Hellstrom et al., 2007; Suchting et al., 2007) .
The induction of a long-term memory response against angiogenesis in general, and DLL4 in particular, raises important safety concerns. Nevertheless, although the available data are limited, studies of vaccination against angiogenesis performed to date show no, or only minor, effects on wound healing or embryonic angiogenesis (Niethammer et al., 2002; Plum et al., 2004) . Likewise, we did not find evidence for a delayed wound healing response following vaccination against DLL4, supporting further development of anti-angiogenic vaccination therapies. However, DLL4 may have other roles in maintaining tissue homeostasis. A recent study showed the emergence of liver toxicity, heart necrosis and benign vascular neoplasms in the skin upon longterm pharmacological blockade of DLL4 (Yan et al., 2010) . No pathological alterations were noted in mice vaccinated against DLL4 for 5 months, indicating that endogenous induction of DLL4-targeting antibodies gives rise to a more balanced inhibition, offering a therapeutic window for the selective treatment of malignant growth. Even so, more careful analyses of organ function and chronic effects are needed to ensure the safety of the procedure.
Little is known about the expression of DLL4 in human tumors. Renal cell carcinomas dramatically upregulate DLL4 specifically in the vasculature, as shown by in situ hybridization, and the expression is correlated to the abundance of VEGF (Patel et al., 2005) . The expression of endothelial DLL4 and VEGF-A is also correlated in colon carcinoma (Jubb et al., 2009) . Our studies indicate that repeated DNA vaccination against DLL4 holds therapeutic efficacy in two different orthotopic mouse models of ERBB2-expressing mammary carcinoma. Interestingly, human breast carcinomas are found to consistently upregulate DLL4 by an average of 25-fold compared with normal breast tissue (Ayyanan et al., 2006) . However, no efforts were made to show whether the expression of DLL4 was restricted to the vasculature. In a separate report, in which an immunostaining approach was used, expression of DLL4 in the endothelium was found to be an independent prognostic factor of an unfavorable outcome in a large selection of breast carcinoma patients (Jubb et al., 2010) . Additional studies examining the correlation of DLL4 expression level or pattern to clinical parameters are thus highly warranted.
Blockade of DLL4 signaling was recently shown to reduce the frequency of tumor-initiating cells in xenografts of colon carcinoma (Hoey et al., 2009) , indicating that there may be additional benefits from inhibition of DLL4 signaling, in addition to the overt anti-angiogenic effects. Nevertheless, it is likely that the therapeutic potential of a vaccination strategy would be best realized in conjunction with clinically approved regimens targeting other cell types within the tumor, such as chemotherapeutic drugs (for example, taxanes), targeted therapy (for example, trastuzumab) or other anti-angiogenic treatments (for example, bevacizumab). Our development of a well-tolerated and efficacious vaccine against pathological angiogenesis by targeting of DLL4 expressed by endothelial tip cells sets the stage for preclinical optimization of the therapeutic regimen in preparation for clinical trials.
Materials and methods

Animal care
All animal studies described were approved by the local committee for animal care (Stockholm North, Sweden).
Plasmids and immunizations
The cDNA encoding human DLL4 (Genecopoeia, Germantown, MD, USA) was cloned into the pVAX1 vector (Invitrogen AB, Carlsbad, CA, USA) using EcoR1 and SalI restriction sites. DNA for immunization was produced by endotoxin-free preparation using the endo-free Giga kit (Qiagen, Hilden, Germany) .
Female BALB/c mice, 6 to 8 weeks old, were immunized three times at the indicated intervals (Figure 1b) , either by intramuscular injection of 80 mg DNA in musculus tibialis or by intradermal injection of 2 Â 40 mg DNA immediately followed by electroporation. Intradermal electroporation (2 pulses, 1125 V/cm, 50 ms; þ 8 pulses, 275 V/cm, 10 ms) of the injection sites was performed using the Derma Vax electroporation system (Cyto Pulse Sciences, Inc., Glen Burnie, MD, USA).
Western blot
Expression of the plasmid vaccine protein product was verified by transient transfection of HeLa cells using Lipofectamine LTX (Invitrogen AB). Cells were harvested after 48 h and subjected to western blot using a rabbit polyclonal antibody against DLL4 (R&D Systems, Minneapolis, MN, USA).
Cell lines and tumor challenge experiments
The BALB/c breast carcinoma cell lines, TUBO and D2F2/E2, were kindly provided by Prof Guido Forni (University of Turin, Italy) and Prof Wei-Zen Wei (Wayne State University, MI, USA), respectively. For tumor challenge experiments, the mice received orthotopic injections of 1 Â 10 6 TUBO or D2F2/ E2 cells in the fourth inguinal mammary fat pad.
Enzyme-linked immunosorbent assay
Plates were coated overnight at 4 1C with 2 pmol of recombinant human DLL4 (Bioinvent International, Lund, Sweden) or 1 pmol of recombinant mouse DLL4 (R&D Systems) per well in 50 ml of 0.1 M sodium carbonate, pH 9.5. The sera were serially diluted and incubated on the plates for 1 h at room temperature, and after the washes bound antibodies were detected by the use of alkaline phosphatase-conjugated secondary antibodies (Applied Biosystems, Carlsbad, CA, USA).
ELISpot
Kits for mouse IFN-g ELISpot assay were obtained from Mabtech AB, Nacka, Sweden. Briefly, splenocytes from immunized mice were purified by ficoll (GE Healthcare Life Sciences, Uppsala, Sweden) separation, and 2 Â 10 5 cells per well were added to the plate. DLL4-specific stimulation was performed with mouse DLL4 9-mer peptides derived from the intracellular portion of DLL4 or the recombinant extracellular portion of DLL4 (R&D Systems) at a final concentration of 5 mg/ml. The carcinoembryonic antigen BALB/c 9-mer peptide CEA 234 (Thermo Fisher Scientific, Ulm, Germany) or recombinant carcinoembryonic antigen (Protein Sciences, Meriden, CT, USA) were used as negative controls. The polyclonal stimulant concanavalin A was used as a positive control.
Immunostaining and quantification of vascular density and perfusion Mice were injected intravenously with 50 ml of fluoresceinlabeled tomato lectin (Vector laboratories, Burlingame, CA, USA), which was allowed to circulate for 4 min before the mice were heart perfused with 10 ml of ice cold 0.9% NaCl solution (phosphate-buffered), followed by 10 ml of 4% paraformaldehyde. Tumors were excised and frozen in optimal cutting temperature compound. Tissue sections were air dried, fixed in acetone and blocked using serum-free protein block (DAKO, Glostrup, Denmark). Immunostaining for CD31 was performed using the MEC13.3 antibody (BD Biosciences, Franklin Lakes, NJ, USA), for DLL4 using a rabbit polyclonal antibody (R&D Systems). Vascular density and perfusion were quantified as the percentage of positively staining area, as determined in 10 high power fields per mouse for five mice in each group.
Microscope image acquisition
Imaging was performed using a Nikon Eclipse E800 microscope equipped with Nikon Plan Fluor objectives ( Â 10, NA 0.30; Â 20, NA 0.50; Â 40, NA 0.75, Nikon Instruments Europe, Amstelveen, The Netherlands) at room temperature in air using Alexa 594 and Alexa 488-coupled secondary antibodies. Images were acquired using a SPOT RTKE camera (Diagnostic Instruments, Sterling Heigths, MI, USA) using the SPOT advanced software.
T cell depletion Depletion of either CD4
þ or CD8 þ T cells from DLL4-vaccinated mice was initiated by injection of 200 mg of rat anti-CD4 (GK1.5) or rat anti-CD8 (TIB-105) antibodies (ATCC) 3 days before tumor challenge. Rat IgG was used as a negative control (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Mice received additional weekly intraperitoneal injections for the duration of the experiment. T cell depletion was verified by flow cytometric analysis after staining of the peripheral blood cells for CD4 and CD8 (BD Biosciences).
Serum transfer
Serum from animals immunized with empty vector or the DLL4 vector was collected at sacrifice, pooled and diluted 1:3 with 0.9% NaCl solution (phosphate-buffered). Serum transfer was performed by intraperitoneal injection of 30 ml of serum to P3 NMRI pups or of 300 ml of serum directly after tumor inoculation of naı¨ve mice, and twice weekly for the duration of the experiment.
Analysis of retinal angiogenesis
Retinas were removed from P5 NMRI pups and wholemounted. The vasculature was visualized by staining with biotinylated isolectinB4 (Sigma-Aldrich, St Louis, MO, USA) followed by streptavidin-Alexa488 (Invitrogen).
Wound model and analysis
The wound healing assay was performed as described previously (Botusan et al., 2008) on mice immunized according to protocol 1. Briefly, general anesthesia was performed with 3% isoflurane and the hair of the back was shaved with an electric clipper followed by a depilatory cream. The skin was rinsed with alcohol and two full-thickness wounds extending through the pannicullus carnosus were made on the dorsum on each side of midline, using a 6-mm biopsy punch. Following the surgical procedure, the animals were individually housed. During the first 2 days the animals received subcutaneous bupremorphine (0.03 mg/kg) twice a day for relief of any possible distress caused by the procedure. Each treatment was evaluated in eight animals per group. Digital photographs were recorded at the day of surgery and every other day after wounding. A circular reference was placed alongside to permit the correction for the distance between the camera and the animals. The wound area was calculated in pixels, using the Image J 1.32 (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/), corrected for the area of the reference circle and expressed as percent of the original area.
Statistical analysis
Statistical analyses were performed using the unpaired, twotailed Student's t-test or repeated-measures ANOVA (wound healing) with a ¼ 0.05.
